Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04349956 · ClinicalTrials.gov registry record
Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo
A clinical trial, sponsored by Unity Biotechnology.
- Terminated
- Registry status
- 161
- Enrollment target
NCT04349956: Clinical Trial study, sponsored by Unity Biotechnology.
NCT04349956 is a clinical trial that was terminated before completion, run by Unity Biotechnology. The registered enrollment target is 161 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04349956 was terminated before completion, sponsored by Unity Biotechnology.
- TERMINATED
- Registry status
- 161 participants
- Enrollment target
Study Summary
A follow-up study to assess the long-term safety of intra-articular (IA) administration of UBX0101 in patients with painful knee osteoarthritis (OA).
Interventions
- DRUG UBX0101 or placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2020-04-20 |
| Est. Completion | 2020-11-02 |
Why NCT04349956 stopped before completion
NCT04349956 is an observational study that tracks outcomes without assigning an intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which UBX0101 or placebo is the first listed.
NCT04349956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04349956 about?
NCT04349956 is a clinical study titled "Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo". A follow-up study to assess the long-term safety of intra-articular (IA) administration of UBX0101 in patients with painful knee osteoarthritis (OA).
What is the current status of trial NCT04349956?
This trial is currently terminated. The enrollment target is 161 participants. The study started on 2020-04-20. Estimated completion is 2020-11-02.
What interventions are being tested in trial NCT04349956?
The interventions under investigation include: UBX0101 or placebo (DRUG).
Who is sponsoring clinical trial NCT04349956?
This trial is sponsored by Unity Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI